irinotecan has been researched along with loperamide in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abigerges, D; Armand, JP; de Costa, L; Gonçalves, E | 1 |
| Abigerges, D; Armand, JP; Chabot, GG; Cote, C; Da Costa, L; Fadel, E; Gandia, D; Hérait, P | 1 |
| Burris, HA; Eckardt, JR; Eckhardt, SG; Elfring, GL; Hilsenbeck, SG; Kuhn, JG; Nelson, J; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Schaaf, LJ; Smith, LS; Thurman, AM; Von Hoff, DD; Weiss, GR | 1 |
| Armand, JP; Couteau, C; Goncalves, E; Terret, C; Yakendji, K | 1 |
| Bastian, G; Bonnay, M; Cote, C; Cvitkovic, E; Hagipantelli, R; Herait, P; Mahjoubi, M; Mignard, D; Misset, JL; Saliba, F; Vassal, G | 1 |
| Droege, CM; Hausamen, TU; Lenfers, BH; Loeffler, TM | 1 |
| Adjei, AA; Alberts, SA; Burch, PA; Elfring, G; Erlichman, C; Goldberg, RM; Miller, LL; Pitot, HC; Reid, JM; Rubin, J; Schaaf, LJ; Skaff, PA; Sloan, JA | 1 |
| Ikari, A; Sakai, H; Suzuki, T; Takeguchi, N | 1 |
| Barbounis, V; Demiri, M; Efremidis, AP; Koumakis, G; Vassilomanolakis, M | 1 |
| Kullmann, F; Schölmerich, J; Schultz, M | 1 |
| Jahnke, K; Keilholz, U; Schmittel, A; Thiel, E | 1 |
| Alimonti, A; Cognetti, F; Di Palma, M; Ferretti, G; Gelibter, A; Pavese, I; Rasio, D; Satta, F; Vecchione, A | 1 |
| Hong, Y; McLachlan, AJ; Rivory, LP; Seale, JP; Tobin, PJ | 1 |
| Benson, A; Wisinski, K | 1 |
| Andrade, AC; Barrios, CH; Chinen, RN; Correa, M; Coutinho, AK; del Giglio, A; Dutra, C; Forones, NM; Hoff, PM; Passos, VQ; Portella, Mdo S; Saragiotto, DF; van Eyll, B | 1 |
4 review(s) available for irinotecan and loperamide
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Enzyme Inhibitors; Glucuronidase; Glucuronides; Glucuronosyltransferase; Humans; Intestines; Irinotecan; Loperamide; Topoisomerase I Inhibitors | 2004 |
7 trial(s) available for irinotecan and loperamide
| Article | Year |
|---|---|
Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Neoplasms | 1994 |
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Topics: Adenocarcinoma; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Irinotecan; Loperamide; Salvage Therapy; Survival Analysis; Treatment Outcome | 1996 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Prospective Studies; Thiorphan | 1998 |
Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Budesonide; Camptothecin; Diarrhea; Female; Fluorouracil; Glucocorticoids; Humans; Irinotecan; Loperamide; Male; Middle Aged; Treatment Failure | 1999 |
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Topics: Adjuvants, Anesthesia; Adult; Aged; Aged, 80 and over; Antidiarrheals; Antiemetics; Antineoplastic Agents, Phytogenic; Area Under Curve; Atropine; Camptothecin; Colorectal Neoplasms; Dexamethasone; Digestive System; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Follow-Up Studies; Gallbladder Neoplasms; Glucuronates; Humans; Irinotecan; Loperamide; Male; Maximum Tolerated Dose; Middle Aged; Time Factors | 2000 |
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Delayed-Action Preparations; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Loperamide; Male; Middle Aged; Octreotide; Quality of Life; Severity of Illness Index; Young Adult | 2014 |
11 other study(ies) available for irinotecan and loperamide
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Neprilysin; Randomized Controlled Trials as Topic; Thiorphan | 1995 |
Inhibition of thromboxane A(2)-induced Cl(-) secretion by antidiarrhea drug loperamide in isolated rat colon.
Topics: Animals; Antidiarrheals; Calcium; Camptothecin; Chlorides; Colon; Dinoprostone; Female; In Vitro Techniques; Irinotecan; Loperamide; Naloxone; Rats; Rats, Wistar; Thromboxane A2 | 2000 |
Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Octreotide; Prospective Studies; Treatment Failure | 2001 |
[Management of chemotherapy induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Loperamide; Neoplasms; Octreotide; Patient Care Management; Practice Guidelines as Topic | 2004 |
Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
Topics: Administration, Oral; Anti-Bacterial Agents; Antidiarrheals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Loperamide; Neomycin | 2004 |
Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
Topics: Animals; Antidiarrheals; Antineoplastic Agents, Phytogenic; Area Under Curve; Bile; Biotransformation; Camptothecin; In Vitro Techniques; Irinotecan; Liver; Loperamide; Male; Rats; Rats, Sprague-Dawley | 2005 |
Chemotherapy-induced mucositis: focusing on diarrhea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Budesonide; Camptothecin; Dehydration; Diarrhea; Fluorouracil; Gastric Mucosa; Gastrointestinal Tract; Humans; Infusions, Intravenous; Intestinal Absorption; Intestinal Mucosa; Irinotecan; Leucovorin; Loperamide; Mice; Mucositis; Organoplatinum Compounds; Rats | 2007 |